• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role.

作者信息

Anesi George L, Maguire Christina

机构信息

Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Department of Pharmacy, Penn Presbyterian Medical Center, Philadelphia, Pennsylvania.

出版信息

Ann Intern Med. 2023 Jan;176(1):133-134. doi: 10.7326/M22-3427. Epub 2022 Dec 13.

DOI:10.7326/M22-3427
PMID:36508735
Abstract
摘要

相似文献

1
Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role.用于非住院COVID-19患者的奈玛特韦片/利托那韦片组合包装：证据不断扩展，作用日益凸显。
Ann Intern Med. 2023 Jan;176(1):133-134. doi: 10.7326/M22-3427. Epub 2022 Dec 13.
2
Nirmatrelvir Plus Ritonavir for COVID-19: The First Step Is Getting the Name Right.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装：首要之事是正确命名。
Mil Med. 2023 Jan 4;188(1-2):34-35. doi: 10.1093/milmed/usac359.
3
Comment on "Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19".关于“奈玛特韦联合利托那韦与非住院肥胖COVID-19患者结局之间的关联”的评论
Int J Antimicrob Agents. 2024 Feb;63(2):107063. doi: 10.1016/j.ijantimicag.2023.107063. Epub 2023 Dec 14.
4
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.进一步分析表明，对于新冠病毒病，奈玛特韦/利托那韦比莫努匹韦疗效更佳。
J Med Virol. 2024 Feb;96(2):e29464. doi: 10.1002/jmv.29464.
5
Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.关于“新型冠状病毒肺炎感染的肾移植受者中奈玛特韦/利托那韦与他克莫司相互作用的管理：三例系列病例”的通信
Eur J Hosp Pharm. 2024 Feb 22;31(2):178-179. doi: 10.1136/ejhpharm-2023-003701.
6
Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.管理 COVID-19 感染的肾移植受者中奈玛特韦/利托那韦和他克莫司的相互作用：三例系列报告。
Eur J Hosp Pharm. 2024 Feb 22;31(2):175-177. doi: 10.1136/ejhpharm-2022-003544.
7
Cost-effectiveness analysis of ritonavir boosted nirmatrelvir for adult outpatients with mild to moderate COVID-19 in a European health system.在欧洲卫生系统中，利托那韦增强型奈玛特韦用于治疗轻至中度COVID-19成年门诊患者的成本效益分析。
Eur J Intern Med. 2023 Dec;118:133-135. doi: 10.1016/j.ejim.2023.09.025. Epub 2023 Oct 7.
8
Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.基于生理的药代动力学模型指导下口服抗凝药物在 COVID-19 治疗中起始使用奈玛特韦/利托那韦（Paxlovid）的剂量管理。
Clin Pharmacol Ther. 2022 Oct;112(4):803-807. doi: 10.1002/cpt.2687. Epub 2022 Jul 4.
9
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.帕克洛维德药物说明书中列出的相互作用，根据风险、药物类别和后果进行分类。
Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13.
10
Nirmatrelvir-ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.

引用本文的文献

1
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.阿兹夫定与奈玛特韦/利托那韦治疗老年重症新型冠状病毒肺炎患者的抗病毒疗效及生存相关性：一项回顾性真实世界研究
EClinicalMedicine. 2024 Feb 9;69:102468. doi: 10.1016/j.eclinm.2024.102468. eCollection 2024 Mar.
2
The Penn Medicine COVID-19 Therapeutics Committee-Reflections on a Model for Rapid Evidence Review and Dynamic Practice Recommendations During a Public Health Emergency.宾夕法尼亚大学医学部新冠治疗委员会——关于公共卫生紧急事件期间快速证据审查及动态实践建议模式的思考
Open Forum Infect Dis. 2023 Aug 9;10(8):ofad428. doi: 10.1093/ofid/ofad428. eCollection 2023 Aug.